Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib [1]

J. Dengler; N. von Bubnoff; T. Decker; C. Peschel; Justus Duyster

doi:10.1038/sj.leu.2403848

Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib [1]

J. Dengler, N. von Bubnoff, T. Decker, C. Peschel, Justus Duyster^*

^*Corresponding author for this work

Clinic of Hematology and Oncology

Technical University of Munich

20 Citations (Scopus)

Original language	English
Journal	Leukemia
Volume	19
Issue number	10
Pages (from-to)	1835-1838
Number of pages	4
ISSN	0887-6924
DOIs	https://doi.org/10.1038/sj.leu.2403848
Publication status	Published - 10.2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.leu.2403848

Cite this

@article{bbb4a4315b0d4ad8955219933b14787a,

title = "Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib [1]",

author = "J. Dengler and {von Bubnoff}, N. and T. Decker and C. Peschel and Justus Duyster",

year = "2005",

month = oct,

doi = "10.1038/sj.leu.2403848",

language = "English",

volume = "19",

pages = "1835--1838",

journal = "Leukemia",

issn = "0887-6924",

number = "10",

}

TY - JOUR

T1 - Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib [1]

AU - Dengler, J.

AU - von Bubnoff, N.

AU - Decker, T.

AU - Peschel, C.

AU - Duyster, Justus

PY - 2005/10

Y1 - 2005/10

UR - http://www.scopus.com/inward/record.url?scp=27144467127&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403848

DO - 10.1038/sj.leu.2403848

M3 - Letters

C2 - 15990864

AN - SCOPUS:27144467127

SN - 0887-6924

VL - 19

SP - 1835

EP - 1838

JO - Leukemia

JF - Leukemia

IS - 10

ER -

Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib [1]

UN SDGs

Access to Document

Other files and links

Cite this